Exact Sciences launches studies to expand its attack on cancer

Exact Sciences Corp. is looking at two new targets for cancer screening: blood cancers and melanoma.

The company also has begun a study to see if its flagship product, the Cologuard stool test for colorectal cancer, is as good at finding the illness in younger people, starting at age 45.

Exact officials have not made any public comment about developing screening tests for blood cancer or melanoma, but the Madison company has registered its plans for the studies, which are listed on ClinicalTrials.gov, a website maintained by the National Institutes of Health. The proposals show that both of those studies were expected to start last month and run through February 2020.